Phase I study of multiple dose intramuscularly administered recombinant gamma interferon

R. Kurzrock, J. R. Quesada, M. Talpaz, Evan M Hersh, J. M. Reuben, S. A. Sherwin, J. U. Gutterman

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-γ). Forty-four patients with metastatic cancer were given rIFN-γ at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-γ resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for antiinterferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regressison consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-γ are indicated.

Original languageEnglish (US)
Pages (from-to)1101-1109
Number of pages9
JournalJournal of Clinical Oncology
Volume4
Issue number7
StatePublished - 1986
Externally publishedYes

Fingerprint

Interferon-gamma
Natural Killer Cells
B-Cell Antigen Receptors
Agranulocytosis
Maximum Tolerated Dose
Lymphoproliferative Disorders
Sweat
Muramidase
Major Histocompatibility Complex
Serum
Immune System
Neoplasms
Leukocytes
B-Lymphocytes
Fever
Cell Count
Macrophages
Antigens
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kurzrock, R., Quesada, J. R., Talpaz, M., Hersh, E. M., Reuben, J. M., Sherwin, S. A., & Gutterman, J. U. (1986). Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. Journal of Clinical Oncology, 4(7), 1101-1109.

Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. / Kurzrock, R.; Quesada, J. R.; Talpaz, M.; Hersh, Evan M; Reuben, J. M.; Sherwin, S. A.; Gutterman, J. U.

In: Journal of Clinical Oncology, Vol. 4, No. 7, 1986, p. 1101-1109.

Research output: Contribution to journalArticle

Kurzrock, R, Quesada, JR, Talpaz, M, Hersh, EM, Reuben, JM, Sherwin, SA & Gutterman, JU 1986, 'Phase I study of multiple dose intramuscularly administered recombinant gamma interferon', Journal of Clinical Oncology, vol. 4, no. 7, pp. 1101-1109.
Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben JM, Sherwin SA et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. Journal of Clinical Oncology. 1986;4(7):1101-1109.
Kurzrock, R. ; Quesada, J. R. ; Talpaz, M. ; Hersh, Evan M ; Reuben, J. M. ; Sherwin, S. A. ; Gutterman, J. U. / Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 7. pp. 1101-1109.
@article{1a376f55925d4160910d92c7cdfb9d4f,
title = "Phase I study of multiple dose intramuscularly administered recombinant gamma interferon",
abstract = "We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-γ). Forty-four patients with metastatic cancer were given rIFN-γ at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-γ resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for antiinterferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regressison consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-γ are indicated.",
author = "R. Kurzrock and Quesada, {J. R.} and M. Talpaz and Hersh, {Evan M} and Reuben, {J. M.} and Sherwin, {S. A.} and Gutterman, {J. U.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "1101--1109",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Phase I study of multiple dose intramuscularly administered recombinant gamma interferon

AU - Kurzrock, R.

AU - Quesada, J. R.

AU - Talpaz, M.

AU - Hersh, Evan M

AU - Reuben, J. M.

AU - Sherwin, S. A.

AU - Gutterman, J. U.

PY - 1986

Y1 - 1986

N2 - We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-γ). Forty-four patients with metastatic cancer were given rIFN-γ at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-γ resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for antiinterferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regressison consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-γ are indicated.

AB - We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-γ). Forty-four patients with metastatic cancer were given rIFN-γ at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-γ resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for antiinterferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regressison consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-γ are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0022542594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022542594&partnerID=8YFLogxK

M3 - Article

C2 - 3088221

AN - SCOPUS:0022542594

VL - 4

SP - 1101

EP - 1109

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -